BioRestorative Therapies, Inc.

Sartorius was a great help in the optimization and validation of their PCR based mycoplasma detection system which allows us to bring our release testing in house. In doing so we have drastic time savings on release testing which is extremely valuable to us.  Follow the link to access their webinar if you’d like to learn more.   Watch the full webinar: https://ow.ly/kl5e50UWJeH

https://lnkd.in/emQQYV3d

BioRestorative Therapies’ Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine https://lnkd.in/gNw9iBYV Mr. Silva has extensive experience in developing and translating cell-based therapeutics. At BioRestorative, he leads a team of scientists developing cell-based therapeutics targeting musculoskeletal and metabolic disorders. Currently, he is the principal investigator of an ongoing Phase 2 study investigating the use of BRTX-100, the Company’s lead cell therapy clinical-stage candidate, in treating chronic lumbar disc disease (cLDD). More recently, Mr. Silva began developing BioRestorative’s novel allogeneic, off-the-shelf ThermoStem® metabolic disease program. Through that work, he was the first to develop an artificial 3D brown adipose transplant using human brown adipose stem cells.

Frustrated by low back pain? Local study doctors are studying a one-time investigational treatment for low back pain that uses your own stem cells. No cost to participate. https://lnkd.in/giuHbXnh

 https://lnkd.in/emKXtNZC

BRTX-100 is a novel product to treat damaged, degenerating discs, and is anticipated to be safer, cheaper, and more effective upon a single treatment. Specifically, BRTX-100 is an autologous stem cell product that uses your own stem cells that are harvested, cultured, and then injected directly into the affected disc to start the repair process. We have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat persistent lower back pain due to painful degenerative discs. https://lnkd.in/eFfmdjNX

BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem ® Metabolic Disease Program 🔵 Brown adipose derived stem cells with brown adipogenic potential would represent a new modality for the treatment of obesity and related metabolic disorders. 🔵 ThermoStem ® is an off-the-shelf platform, well-protected by a comprehensive portfolio of issued patents that cover both the U.S. and international markets. 🔵 Potential license partner is a leading commercial stage regenerative medicine company. 👉Read the full press release here: https://lnkd.in/epTs4uYt

Regenerative Medicine Revenue to Hit $49.0B by 2028 Download Free PDF Brochure: https://lnkd.in/diA3SH9a The global regenerative medicine market, valued at $16.0 billion in 2023, is anticipated to reach $49.0 billion by 2028, growing at a CAGR of 25.1% during the forecast period from 2023 to 2028. Novartis Biogen Gilead Sciences Sarepta Therapeutics Amgen Smith+Nephew Medipost JCR Pharmaceuticals Co Ltd Co., Ltd. TakedaPharmaceutical Nordics AB Corestem Inc. Vericel® Corporation MiMedx Organogenesis Medtronic Bristol Myers Squibb Orthocell Ltd. Mesoblast Limited BioRestorative Therapies, Inc. Tego Science Inc. Anterogen bluebird bio Stempeutics Research Private Limited Aspect Biosystems Athersys